Skip to main content
. 2011 Dec 30;5:135–143. doi: 10.2174/1874285801105010135

Table 5.

RSV Rehospitalization Rates in Preterm Infants with and Without Bronchopulmonary Dysplasia Having Received Palivizumab from the Palivizumab Outcomes Registry [64]

2000-2001 (n= 2049) 2001-2002 (n=5084) 2002-2003 (n=6291) 2003-2004 (n=6050)
All preterm infants 2,9 1,5 1,1 0,7
without BPD/ CLD 2,1 1,2 1,2 0,7
< 32 weeks 4,5 1,7 1,6 1,1
32-35 weeks 1,6 1,3 0,7 0,2
BPD/ CLD 5,8 2,2 1,9 1,8